Tasuku completed his M.S. (2002) and Ph.D. (2005) at the University of Tokyo. After obtaining his Ph.D. degree, he joined Eisai Co. Ltd. as a medicinal chemist, developing new chemical entities in the area of neuroscience. In 2011, Eisai established a new subsidiary, H3 Biomedicine Inc. in Massachusetts, US, and he was assigned there as a senior investigator to construct diversity-oriented synthesis (DOS) libraries. After returning to Japan in 2015, he joined the Oncology Business Group as a senior scientist to develop novel cancer therapies. Starting in 2019, he is in Prof. Alessio Ciulli's group at the University of Dundee to promote collaborative research between Ciulli's group and Eisai to develop novel types of protein degraders that could be used to treat cancers.